Summary
Phencyclidine (PCP) is a dissociative drug and an antagonist of N-methyl-D-aspartate (NMDA) receptor. The effects of PCP treatment on neuropeptide Y (NPY) system in the arcuate nucleus of the rat hypothalamus were examined both by immunocytochemistry and in situ hybridization. In acute PCP-treated rats, the NPY-immunoreactive perikarya appeared in the arcuate nucleus but no perikarya were detected in controls, without colchicine pretreatment. The signals of NPY mRNA by in situ hybridization increased in the PCP-treated rats than those of controls. These results suggest that the NPY system in the arcuate nucleus might be partly controlled by glutamatergic neurons.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, Polack JM (1983) Neuropetide Y distribution in the rat brain. Science 221: 877–879
Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate. Br J Pharmacol 790: 565–575
Chapman CD, Gazzara RA, Howard SG (1990) Effects of phencyclidine on extracellular levels of dopamine, dihydroxyphenylacetic acid and homovanillic acid in conscious and anesthetized rats. Neuropharmacology 29: 319–325
Contreras PC, Monaham JB, Lanthorn TH, Pullan LM, DiMaggio DA, Handelman GE, Gray NM, O'Donohue TL (1987) Phencyclidine. Mol Neurobiol 1: 191–210
Everitt BJ, Hokfelt K, Terenius L, Tatemoto K, Mutt V, Goldstein M (1984) Differential coexistence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat. Neurosci 11: 443–462
Fukui K, Miyaka M, Matsumoto Y, Lizumi H, Okamoto S, Kihira S, Okamura H, Ibata Y, Nakajima T (1990) Effects of haloperidol on the neuropeptide Y-like immunoreactivity in the mouse brain. Ann Rep Pharmacopsychiat Res Found 21: 135–140
Fukui K, Kawashima Y, Lizumi H, Utsumi H, Nakajima T (1995) Immunohistochemical alterations in neuropeptide Y-positive nerve elements in rat cerebral cortex following acute phencyclidine treatment. Neuro Report 6: 626–628
Heilig M, Widerlov E (1990) Neuropeptide Y: an overview of central distribution, functional aspects and possible involvement in neuropsychiatrie illness. Acta Psychiatr Scand 82: 95–114
Johnson KM, Jones SM (1990) Neuropharmacology of phencyclidine: basic mechanism and therapeutic potential. Ann Rev Pharmacol Toxicol 30: 707–750
Junien JL, Leonard BE (1989) Drugs acting on sigma and phencyclidine receptors: a review of their nature, function, and possible therapeutic importance. Clin Neuropharmacol 12: 353–374
Li S, Pelletier G (1986) The role of dopamine in the control of neuropeptide Y neurons in the rat arcuate nucleus. Neurosci Lett 69: 74–77
Lillrank SM, O'Connor WT, Oja SS, Ungerstedt U (1994) Systemic phencyclidine administration is associated with increased dopamine, GABA, and 5-HIAA levels in the dorsolateral striatum of conscious rats: an in vivo microdialysis study. J Neural Transm [GenSect] 95: 145–155
Midgley LP, Bush LG, Gibb JM, Hanson GR (1992) Characterization of phencyclidine-induced effects on neuropeptide Y systems in the rat caudate-putamen. Brain Res 593: 89–96
Miyake M, Iguchi K, Okamura H, Fukui K, Nakajima T, Chihara K, Ibata Y, Yanaihara N (1990) Effects of haloperidol on immunoreactive neuropeptide Y in rat cerebral cortex and basal ganglia. Brain Res Bull 25: 263–269
Morris BJ (1989) Neuronal localization of neuropeptide Y gene expression in rat brain. J Comp Neurol 290: 358–368
Nabeshima T, Sivam SP, Norris JC, Ho IK (1981) Calcium-dependent GABA release from mouse brain slices following acute chronic phencyclidine administration. Res Commun Subst Abuse 2: 343–354
Nabeshima T, Yamaguchi K, Hiramatsu M, Amano M, Furukawa H, Kameyama T (1984) Serotonergic involvement in phencyclidine-induced behaviors. Pharmacol Biochem Behav 21: 401–408
O'Donohue TL, Chronwall BM, Pruss RM, Mezey E, Kiss JZ, Eiden LE, Massari VJ, Tessel RE, Pickel VM, DiMaggio DA, Hotchikiss AJ, Crowley WR, Zukowska-Grojec Z (1985) Neuropeptide Y and peptide YY neuronal and endocrine system. Peptide 6: 755–768
Okamoto S, Okamura H, Miyake M, Takahashi Y, Takagi S, Akagi Y, Fukui K, Okamoto H, Ibata Y (1991) A diurnal variation of vasoactive intestinal peptide (VIP) mRNA under a daily light-dark cycle in the rat suprachiasmatic nucleus. Histochem 95: 525–528
Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinate. Academic Press, New York
Peters J, Van Kämmen DP, Gelernter J, Yao J, Shaw D (1990) Neuropeptide Y-like immunoreactivity in schizophrenia: relationships with clinical measures. Schizophr Res 3: 287–294
Snyder SH (1980) Phencyclidine. Nature 285: 355–356
Takeuchi J, Nagasaki H, Shinohara K, Inouye SIT (1992) A circadian rhythm of somatostatin messenger RNA levels, but not of vasoactive intestinal polypeptide/peptide histidine isoleucine messenger RNA levels in rat suprachiasmatic nucleus. Mol Cell Neurosci 3: 29–35
Tatemoto K, Carlquist M, Mutt V (1982) Neuropeptide Y — a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296: 659–660
Van den Pol AN, Wuarin JP, Dudek FE (1990) Glutamate, the dominant exitatory transmitter in neuroendocrine regulation. Science 250: 1276–1278
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fukui, K., Kawashima, Y., Iizumi, H. et al. The effects of acute phencyclidine treatment on neuropeptide Y (NPY) neuronal system in the rat arcuate nucleus studied by immunocytochemistry and in situ hybridization. J. Neural Transmission 103, 385–390 (1996). https://doi.org/10.1007/BF01276415
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01276415